trending Market Intelligence /marketintelligence/en/news-insights/trending/Pw3uFoFSTXEpnltWJJ4e3w2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Sino Biopharmaceutical Q1 profit rises 11.1% YOY


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Sino Biopharmaceutical Q1 profit rises 11.1% YOY

Sino Biopharmaceutical Ltd.'s profit for the first quarter ended March 31 rose 11.1% year-over-year.

Profit attributable to the owners of the parent was about 856.7 million yuan, compared to 771.1 million yuan in the same period a year ago.

EPS attributable to ordinary equity holders of the parent was 6.80 fen, compared to 6.44 fen in the year-ago period.

Revenue for the Hong Kong-based drugmaker rose by 33.4% year over year to 6.21 billion yuan.

As of May 20, US$1 was equivalent to 6.91 yuan.